ESG (Environment, Sustainability, Governance) Strategy to Drive the Prolotherapy Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

According to the National Institutes of Health (NIH), the prevalence of knee pain among the population suffering from arthritis was 32.2% and 58.0% among men and women respectively.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32457

There has been a significant reduction in the number of patient-hospital visits due to the lockdown implement across several countries impacting global prolotherapy market growth. Several biopharmaceuticals are focussed on developing coronavirus cure that leads to delay of research and development activities in global prolotherapy market. The emergence of COVID 19 has also caused the delay of non-emergent procedures having a negative impact on global prolotherapy market growth.

Rise of geriatric population is expected to increase demand for global prolotherapy market during the forecast period. The increasing rate of diagnosis and treatment adoption rate is expected to increase demand for global prolotherapy market during the forecast period. Changing lifestyle and increasing prevalence of obesity will boost global prolotherapy market growth.

Advancement in technology, as well as rise in research and development, is expected to increase investments in global prolotherapy market are the favourable scenarios. For instance, in February 2016 Aurobindo Pharma final approval from the U.S. Food and Drug Administration (FDA) for manufacturing and commercialization of its Dextrose injection in the market.

Side effects of prolotherapy like infection or needle stick injuries are expected to hinder global prolotherapy market growth. Whereas, less adoption of prolotherapy in underdeveloped countries will challenge global prolotherapy market growth during the forecast period.

Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32457

The global prolotherapy market is classified based injectable, application, indication, end-users and region:

Based on the injectable, the global prolotherapy market is segmented into the following:

• Dextrose
• Platelet Rich Plasma
• Bicellular prolo

Based on the application, the global prolotherapy market is segmented into the following:

• Joint injection prolotherapy
• Ligament prolotherapy
• Tendon reconstruction prolotherapy

Based on the indication, the global prolotherapy market is segmented into the following:

• Lower back pain
• Neck pain
• Shoulder pain
• Knee pain
• Elbow pain
• Foot pain
• Plantar fasciitis
• Ankle pain
• Osteoarthritis
• Other musculoskeletal pain or injury

Based on the end-users, the global prolotherapy market is segmented into the following:

• Hospitals
• Ambulatory Care Centers
• Orthopedic Centres
• Speciality Clinics
• Academic and Research Institutes

Based on injectable dextrose is expected to hold a major revenue share in global prolotherapy market with increasing demand for pain relief. Joint injection global prolotherapy has the highest demand in global prolotherapy market with the increasing prevalence of joint pain.

Whereas, based on indication knee pain and osteoarthritis will observe a significant rise in demand in global prolotherapy market. The hospitals segment is estimated to be the largest end-user of global prolotherapy market with the high patient population.

Asia-Pacific region with the rise in healthcare expenditure is expected to observe a significant growth in global prolotherapy market in the coming decade. The Middle East and Africa will observe less growth for global prolotherapy market with less product penetration due to poor health infrastructure in the region.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32457

• Pfizer Inc.
• Baxter International
• B. Braun
• Johnson & Johnson
• Arthex Inc.
• Terumo Corporation
• Aurobindo Pharma
• Shandong Qidu Pharmaceuticals
• Amphastar Pharmaceuticals Inc.
• Sanctus drugs & Pharmaceuticals
• Hospira Pharmaceutical Company
• Others